Replies to post #222656 on Biotech Values

[DewDiligence]

MREO +26% on FDA feedback re early-stage program in ovarian cancer:

https://www.globenewswire.com/news-release/2019/07/15/1882568/0/en/Mereo-BioPharma-Announces-Successful-Type-B-Meeting-with-U-S-FDA-and-Outlines-Accelerated-Approval-Pathway-for-Navicixizumab-in-Advanced-Ovarian-Cancer.html

MREO gained its Nasdaq listing by reverse-merging with OMED (#msg-145273044). It also trades in London as MPH.L.